6431 related articles for article (PubMed ID: 3091371)
1. Difluoromethylornithine and leukocyte interferon: a phase I study in cancer patients.
Talpaz M; Plager C; Quesada J; Benjamin R; Kantarjian H; Gutterman J
Eur J Cancer Clin Oncol; 1986 Jun; 22(6):685-9. PubMed ID: 3091371
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine--an inhibitor of polyamine biosynthesis.
Abeloff MD; Slavik M; Luk GD; Griffin CA; Hermann J; Blanc O; Sjoerdsma A; Baylin SB
J Clin Oncol; 1984 Feb; 2(2):124-30. PubMed ID: 6422008
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of alpha-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma.
Meyskens FL; Kingsley EM; Glattke T; Loescher L; Booth A
Invest New Drugs; 1986; 4(3):257-62. PubMed ID: 3102397
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of alpha-difluoromethylornithine and methyl-GAG.
Splinter TA; Romijn JC
Eur J Cancer Clin Oncol; 1986 Jan; 22(1):61-7. PubMed ID: 3082642
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial of recombinant interferon-alpha and alpha-difluoromethylornithine in metastatic melanoma.
Croghan MK; Booth A; Meyskens FL
J Biol Response Mod; 1988 Aug; 7(4):409-15. PubMed ID: 3139843
[TBL] [Abstract][Full Text] [Related]
6. Phase II trials of alpha-difluoromethylornithine, an inhibitor of polyamine synthesis, in advanced small cell lung cancer and colon cancer.
Abeloff MD; Rosen ST; Luk GD; Baylin SB; Zeltzman M; Sjoerdsma A
Cancer Treat Rep; 1986 Jul; 70(7):843-5. PubMed ID: 3013400
[TBL] [Abstract][Full Text] [Related]
7. Additive and differential biological activity of alpha-interferon A, difluoromethylornithine, and their combination on established human lung cancer cell lines.
Bepler G; Carney DN; Nau MM; Gazdar AF; Minna JD
Cancer Res; 1986 Jul; 46(7):3413-9. PubMed ID: 3085922
[TBL] [Abstract][Full Text] [Related]
8. Sequential inhibition of polyamine synthesis. A phase I trial of DFMO (alpha-difluoromethylornithine) and methyl-GAG [methylglyoxal-bis(guanylhydrazone)].
Warrell RP; Coonley CJ; Burchenal JH
Cancer Chemother Pharmacol; 1983; 11(2):134-6. PubMed ID: 6414731
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of antitumor and antimetastatic activities of alpha-difluoromethylornithine by interferon inducers.
Sunkara PS; Prakash NJ; Rosenberger AL; Hagan AC; Lachmann PJ; Mayer GD
Cancer Res; 1984 Jul; 44(7):2799-802. PubMed ID: 6426786
[TBL] [Abstract][Full Text] [Related]
10. Effects of alpha-difluoromethylornithine and recombinant interferon-alpha 2 on the growth of a human renal cell adenocarcinoma xenograft in nude mice.
Heston WD; Fleischmann J; Tackett RE; Ratliff TL
Cancer Res; 1984 Aug; 44(8):3220-5. PubMed ID: 6430546
[TBL] [Abstract][Full Text] [Related]
11. Phase I evaluation of intravenous difluoromethylornithine--a polyamine inhibitor.
Maddox AM; Keating MJ; McCredie KE; Estey E; Freireich EJ
Invest New Drugs; 1985; 3(3):287-92. PubMed ID: 3934106
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of difluoromethylornithine in combination with recombinant alpha 2a-interferon.
Edmonson JH; Kovach JS; Buckner JC; Kvols LK; Hahn RG
Cancer Res; 1988 Nov; 48(22):6584-6. PubMed ID: 3141046
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma.
Mittelman A; Huberman M; Puccio C; Fallon B; Tessitore J; Savona S; Eyre R; Gafney E; Wick M; Skelos A
Cancer; 1990 Aug; 66(4):664-9. PubMed ID: 2386896
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine.
Love RR; Carbone PP; Verma AK; Gilmore D; Carey P; Tutsch KD; Pomplun M; Wilding G
J Natl Cancer Inst; 1993 May; 85(9):732-7. PubMed ID: 8478959
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of mouse bladder tumor proliferation by alpha difluoromethylornithine and interferon in vitro and in vivo.
Bahnson RR; Ratliff TL
J Urol; 1988 Jun; 139(6):1367-71. PubMed ID: 3131549
[TBL] [Abstract][Full Text] [Related]
16. Clinical phase II trial of recombinant DNA interferon (interferon alpha 2b) in patients with metastatic malignant melanoma.
Dorval T; Palangie T; Jouve M; Garcia-Giralt E; Israel L; Falcoff E; Schwab D; Pouillart P
Cancer; 1986 Jul; 58(2):215-8. PubMed ID: 3719515
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose de-escalation trial of alpha-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia.
Mitchell MF; Tortolero-Luna G; Lee JJ; Hittelman WN; Lotan R; Wharton JT; Hong WK; Nishioka K
Clin Cancer Res; 1998 Feb; 4(2):303-10. PubMed ID: 9516915
[TBL] [Abstract][Full Text] [Related]
18. Phase II assessment of recombinant leukocyte A interferon with difluoromethylornithine in disseminated malignant melanoma.
Creagan ET; Long HJ; Ahmann DL; Schaid DJ
Am J Clin Oncol; 1990 Jun; 13(3):218-20. PubMed ID: 2111969
[TBL] [Abstract][Full Text] [Related]
19. Dose-related alpha-difluoromethylornithine ototoxicity.
Croghan MK; Aickin MG; Meyskens FL
Am J Clin Oncol; 1991 Aug; 14(4):331-5. PubMed ID: 1862765
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial and pharmacokinetic study of intravenous and oral alpha-difluoromethylornithine.
Griffin CA; Slavik M; Chien SC; Hermann J; Thompson G; Blanc O; Luk GD; Baylin SB; Abeloff MD
Invest New Drugs; 1987; 5(2):177-86. PubMed ID: 3115911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
